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ES cells do not activate p53-dependent stress responses and
undergo p53-independent apoptosis in response to DNA damage
Mirit I. Aladjem*, Benjamin T. Spike*, Luo Wei Rodewald*, Thomas J. Hope†,
Martina Klemm‡, Rudolf Jaenisch‡ and Geoffrey M. Wahl*
Background: Embryonic stem (ES) cells can contribute precursors to all adult
cell lineages. Consequently, damage to ES cell genomes may cause serious
developmental malfunctions. In somatic cells, cell-cycle checkpoints limit DNA
damage by preventing DNA replication under conditions that may produce
chromosomal aberrations. The tumor suppressor p53 is involved in such
checkpoint controls and is also required to avoid a high rate of embryonic
malformations. We characterized the cell-cycle and DNA-damage responses of
ES cells to elucidate the mechanisms that prevent accumulation or transmission
of damaged genomes during development. 
Results: ES cells derived from wild-type mice did not undergo cell-cycle arrest
in response to DNA damage or nucleotide depletion, although they synthesized
abundant quantities of p53. The p53 protein in ES cells was cytoplasmic and
translocated inefficiently to the nucleus upon nucleotide depletion. Expression
of high levels of active p53 from an adenovirus vector could not trigger cell-
cycle arrest. Instead, ES cells that sustained DNA damage underwent p53-
independent apoptosis. The antimetabolite-induced p53-dependent arrest
response was restored in ES cells upon differentiation. 
Conclusions: Cell-cycle regulatory pathways in early embryos differ significantly
from those in differentiated somatic cells. In undifferentiated ES cells, p53
checkpoint pathways are compromised by factors that affect the nuclear
localization of p53 and by the loss of downstream factors that are necessary to
induce cell-cycle arrest. A p53-independent programmed cell death pathway is
effectively employed to prevent cells with damaged genomes from contributing
to the developing organism. The p53-mediated checkpoint controls become
important when differentiation occurs.
Background
Cells are constantly subjected to environmental and meta-
bolic conditions that may cause genetic damage. Ionizing
radiation, mutagenic and clastogenic chemicals can induce
mutations or large-scale genome alterations. DNA synthe-
sis or cell division under suboptimal growth conditions
may also cause chromosomal aberrations [1–4]. In
response to these challenges, eukaryotes have developed
cell-cycle control and repair mechanisms. Cell-cycle
checkpoints are signal transduction pathways that ensure
that all of the processes required to execute each phase of
the cell cycle are completed before the next phase is initi-
ated [5]. Cells depleted of nucleotides, for example, may
arrest to avoid replication under suboptimal conditions [6].
Likewise, cells do not enter mitosis before completing
DNA replication [7,8], or if they have unrepaired DNA
damage [5,9]. 
The loss of cell-cycle checkpoints does not affect cell
viability under nondisruptive conditions, but increases
genetic instability subsequent to the challenge
[2,3,5,10–12]. The tumor suppressor p53 is part of a
signal transduction pathway that converts signals ema-
nating from DNA damage, ribonucleotide depletion and
other stresses into responses ranging from cell-cycle
arrest to apoptosis (for reviews, see [11,13,14]). Cells that
are deficient in p53 may fail to undergo cell-cycle arrest
or apoptosis in response to conditions that either lead to
DNA damage [3,15] or perturb the cell cycle [15–22].
These aberrant responses explain why p53-deficient
mice have increased rates of tumorigenicity and genomic
instability [23–25]. The resistance of p53-deficient cells
to DNA-damage-induced apoptosis and their increased
rate of genetic variance result in significant selective
advantages to such cells during tumor progression. As
expected, cells deficient in components of the p53-medi-
ated DNA-damage-response pathway, such as the cyclin-
dependent kinase inhibitor p21 or the retinoblastoma
protein Rb, also show altered responses to environmental
challenges [22,26–28].
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Cells originating from different tissues have dramati-
cally different responses to genotoxic challenge. For
example, γ-irradiation leads to a prolonged cell-cycle
arrest resembling senescence in fibroblasts [29–32],
whereas the same challenge leads to apoptosis in thy-
mocytes and intestinal epithelial cells [33–35]. It is
striking that genetically identical cells situated adjacent
to one another in the same tissue can also have pro-
foundly different responses to DNA damage. For
instance, prostate stromal (fibroblast) cells induce p53
and undergo cell-cycle arrest in response to γ−irradia-
tion but adjacent epithelial cells fail to induce p53 or
undergo cell-cycle arrest [36]. These data are compati-
ble with observations during embryonic differentiation
in vivo, demonstrating that various differentiating
tissues show considerable heterogeneity in stress-
induced transcription from p53-dependent promoters
[37]. These differences in induction of p53 and cell-
cycle arrest imply that signal processing and response
within the DNA-damage-response pathway are regu-
lated in a tissue-specific fashion. 
Although several studies have shown that mouse
embryo fibroblasts (MEFs) are capable of inducing the
p53-dependent cell-cycle arrest in response to diverse
stresses [20,22,24,26,38], the behavior of pluripotent
undifferentiated embryonic cells towards genotoxic
challenge has not been investigated in detail. Because
these cells contribute to all adult cell lineages [39], such
cells should have a highly sensitive and finely tuned
p53-dependent signal transduction pathway to limit the
emergence of genetic variants. This prediction is consis-
tent with previous reports describing robust p53 expres-
sion during early murine embryogenesis [37,40] and
with the modest increase in teratogenicity of
benzo[a]pyrene [12] and irradiation [10] in p53-deficient
mice. Nevertheless, these studies did not examine
whether the conditions that activate p53 in adult tissues
have similar effects on undifferentiated embryonic stem
(ES) cells. 
This report analyzes the consequences of challenging
murine ES cells with antimetabolites or with DNA-dam-
aging agents. We show that p53 is expressed in murine
ES cells and appears to be present mainly in the cyto-
plasm. ES cells failed to undergo cell-cycle arrest in
response to rNTP depletion, DNA damage, and p53
overexpression, however. Interestingly, ES cells were
exquisitely sensitive to DNA damage through the activa-
tion of an apoptotic program that was effectively initiated
in the absence of p53. These results suggest a p53-inde-
pendent, DNA-damage-induced response as the front-
line strategy to insure genomic stability in ES cells.
Finally, we show that an active p53-mediated DNA-
damage-response pathway is activated upon differentia-
tion of ES cells.
Results
ES cells do not arrest after challenge with antimetabolites
and genotoxic agents 
To determine whether ES cells have intact p53-mediated
cell-cycle responses to rNTP depletion and DNA damage,
we analyzed the effects of the antimetabolite n-phospho-
nacetyl-L-aspartate (PALA), γ-irradiation and adriamycin
on the cell cycle [6,15,29]. A baseline assessment of the
cell cycle for ES cells was obtained by pulse labeling
exponentially growing ES cells with bromodeoxyuridine
(BrdU) and analyzing the cells using dual-parameter flow
microfluorimetry (FMF). More than 65% of the ES cells
were in S phase (that is, BrdU-positive cells with DNA
contents ranging from 2N to 4N) after a 10minute expo-
sure to BrdU. BrdU exposure exceeding 40 minutes
resulted in > 90% of cells being labeled. By contrast, only
5–12% of isogenic MEFs were in S phase after a 30minute
BrdU pulse, and a substantial number were in G1 and
G2/M (Figure 1). These data show that ES cells have very
short G1 and G2/M phases and, most probably, oscillate
between S phase and mitosis. 
A comparison of the cell-cycle responses of MEFs and ES
cells following challenge with PALA is shown in Figure 1.
The S-phase fraction of MEFs was markedly reduced
after treatment with 0.1mM PALA, whereas ES cells
treated with as much as 1 mM PALA continued to enter
and progress through S phase (Figure 1a). The cell-cycle
profile of ES cells under PALA treatment was similar to
that of PALA-treated p53-deficient MEFs in that both
failed to arrest during G1 and entered readily into S phase
in the presence of high PALA concentrations (Figure 1b).
In somatic cells, DNA damage results in a rapid decrease
in the S-phase population because a p53-dependent
mechanism prevents G1 cells with DNA damage from
entering S phase [15,29]. As shown in Figure 2, the S-
phase fraction in ES cells harvested 16 hours after expo-
sure to 6 Grays (Gy) ionizing radiation or treated with
1µg/ml adriamycin was similar to the S-phase fraction in
exponentially growing control cells, and no reproducible
increase was seen in the G1 and/or G2 fractions. These
results are similar to the radiation response of p53-defi-
cient MEFs [23,38].
Expression of cell-cycle proteins 
The lack of G1 arrest elicited by either rNTP depletion or
DNA damage suggests that, despite their normal geno-
type, ES cells do not have a functional p53-mediated
DNA-damage-response pathway. To gain an insight into
the mechanisms that prevent cell-cycle arrest in ES cells,
we first determined whether p53 is expressed in ES cells,
and whether its abundance increases subsequent to
appropriate challenges. The activation of p53 should
result in transactivation of downstream target genes
encoding, for example, p21Cip1/Waf1/Sdi1 [41,42] or Mdm2
146 Current Biology, Vol 8 No 3
[43,44]. To test directly for the function of the p53
pathway, we determined whether Mdm2 and p21 are
present in ES cells, and whether their abundance
increases subsequent to irradiation.
The p53 and Mdm2 proteins were immunoprecipitated
from extracts obtained from exponentially growing,
PALA-treated or γ−irradiated ES cells (Figure 3). ES cells
contained a protein that is immunoprecipitated by anti-
serum directed against p53 (IP:p53), but not by a control
antiserum that does not recognize p53 (IP:IA). A small
increase in p53 levels above control levels was observed in
γ-irradiated (Figure 3, lanes 2 and 4), but not in PALA-
treated (Figure 3, lane 6) ES cells. These results demon-
strate that the p53 protein is expressed in ES cells, but
that it is not induced significantly following PALA treat-
ment or irradiation. 
The p53 protein forms complexes with Mdm2 that target
p53 for degradation [45,46]. Figure 3 shows that
p53–Mdm2 complexes exist in ES cells, but that Mdm2
levels were not increased significantly by PALA treat-
ment or γ-irradiation. The precipitating antibody used,
sc-965, is a monoclonal antibody directed against a region
of the Mdm2 protein (amino acids 154–167) which shares
low homology with MdmX, a related protein that is not
induced by p53 [47]. The detected protein migrated
with an apparent molecular weight of 90 kDa, which is
characteristic of Mdm2 and not of MdmX, which has an
apparent molecular weight of 70 kDa. Exogenous p53,
expressed by the adenovirus ACNp53, was able to
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Cell-cycle response of ES cells to rNTP depletion by the antimetabolite
PALA. (a) ES cells were exposed for 48 h to 1 mM PALA and MEFs to
0.1 mM PALA. The exposed cells and untreated control cells were
labeled with BrdU, harvested and analyzed by FMF. The horizontal axis
depicts the DNA content and the vertical axis indicates BrdU
incorporation on a logarithmic scale. The percentage of cells in S
phase is indicated in the upper left corner of each panel. PI, propidium
iodide; FITC, fluorescein isothiocyanate. (b) Summary of cell-cycle
analyses (4–10 repetitions) of ES cells, MEFs and p53–/– MEFs
exposed to PALA. 
Figure 2
Cell-cycle response of ES cells to DNA-damaging agents. Cells were
exposed to 6 Gy γ-irradiation and to adriamycin (ADR) at the indicated
concentrations. Cells were harvested 16 h after exposure to irradiation
or to the drug. Similar cell-cycle profiles were obtained after exposure
to 4–10 Gy of γ-irradiation and to 1 µg/ml adriamycin in at least four
independent experiments. 
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increase the levels of both p53 and Mdm2 (Figure 3, lane
7). It should be noted that the overall steady-state level of
Mdm2 was very low; we were unable to detect it directly
in immunoblots or by immunocytochemistry (data not
shown). Similarly, we were unable to detect p21 in ES
cells using immunoblots, by immunofluorescence or
northern hybridization analyses (data not shown), indicat-
ing that p53 was not functioning as an efficient transcrip-
tional activator for these targets in ES cells. These data
are consistent with the results of Savatier et al. [48], who
did not observe p21 in undifferentiated ES cells. 
The p53 protein is cytoplasmic in ES cells and is
translocated inefficiently into the nucleus in response to
rNTP depletion 
PALA treatment and irradiation typically result in effi-
cient translocation of p53 from the cytoplasm to the
nucleus [6,49,50]. We used immunocytochemistry to
determine whether the apparent inactivity of p53 in ES
cells might result from inefficient nuclear translocation. As
shown in Figure 4a,b, PALA treatment of MEFs resulted
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Figure 4
Expression and cellular localization of p53 in ES cells and MEFs.
Cells were grown on coverslips (5 × 105 ES cells and 1 × 105 MEFs),
infected with p53 expression viruses or treated with PALA and
expression was detected by immunofluorescence. (a–f) Antibody
Do-1 was used to detect p53. Antibody staining was detected with
fluorescein isothiocyanate (FITC; green) and nuclei were
counterstained with Hoechst 33352 (blue). Panels (a), (c) and (e)
are composites showing FITC stain and nuclear Hoechst 33352
counterstain. Panels (b), (d) and (f) were photographed with an FITC
filter (to detect FITC only). (a) MEFs immunostained for p53
expression; (b) MEFs treated with PALA, immunostained for p53
expression; (c) ES cells immunostained for p53 expression; (d) Same
cells as in (c), photographed with an FITC filter (the inset shows
similar cytoplasmic staining of cells to the cytoplasmic marker β-
actin; (e) ES cells infected with 5 × 109 particles of the p53-
expressing virus AMNp53; (f) ES cells infected with 5 × 1010
particles of the p53-expressing virus AMNp53. The size bars are
50 µm. (g) Confocal micrographs. ES cells were grown in chamber
slides, treated as indicated and processed for microscopy as above,
except that the Hoechst staining was replaced by staining with
propidium iodide (PI; red) in the presence of RNAse. The p53 protein
was immunostained using antibody pAb421. Upper panels,
combined FITC and PI signal; lower panels, FITC signal only. PCNA,
proliferating cell nuclear antigen. Current Biology
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Expression of p53 and Mdm2 in ES cells. Extracts from ES cells were
precipitated with antibody 421 against p53 (IP:p53) or antibody
sc-965 against Mdm2 (IP:Mdm2). An irrelevant antibody (anti-BrdU)
that does not react with p53 was used as a control for
immunoprecipitation specificity (IP:IA). Immunocomplexes were
detected with antibody sc-812 against Mdm2 or antibody Do-1 against
p53. Lanes 1,3 and 5, control untreated cells; lanes 2 and 4,
γ-irradiated cells (extracts prepared 18 h after irradiation); lane 6, cells
exposed to PALA for 18 h; lane 7, cells infected with an adenovirus
(ACNp53) expressing wild-type human p53.
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in a striking nuclear localization of p53 in >90% of the
cells. By contrast, most of the p53 was localized in the
cytoplasm of ES cells (Figure 4c,d,g) and a significant het-
erogeneity in p53 distribution was observed in PALA-
treated cells (Figure 4g). Some PALA-treated cells had a
significant increase in nuclear p53 levels, but many
showed little, if any, nuclear accumulation. These results
indicate that the mechanism responsible for cytoplas-
mic–nuclear shuttling of p53 is less efficient in ES cells
than in fibroblasts. 
Inability to restore cell-cycle arrest upon infection with
wild-type human p53
We tested whether high levels of wild-type p53 might
overcome the inability of ES cells to activate cell-cycle
arrest. ES cells were infected with replication-deficient
adenoviruses expressing wild-type human p53, that had
previously been shown to induce cell-cycle arrest in
human and murine cells [6,51]. Immunoblot analyses indi-
cated that infection with the adenovirus resulted in p53
overexpression (Figure 3, lane 7; Figure 4e,f). The p53
protein was present in the cell nuclei, but because of the
fluorescent intensity of the overproduced protein and the
small size of the cells, it was impossible to discern whether
some p53 was also present in the cytoplasm. As shown in
Figure 5, infected cells had a cell-cycle profile that was
similar to that of uninfected ES cells. PALA treatment of
the infected cells did not cause cell-cycle arrest despite
the high levels of p53. These data suggest that ES cells
have a very effective mechanism for rendering them
refractory to p53 function, even when they contain sub-
stantial quantities of nuclear p53.
Induction of p53-independent apoptosis in ES cells upon
DNA damage
The apparent inability of ES cells to mount a p53-depen-
dent cell-cycle arrest in response to rNTP depletion or
DNA damage raises the important issue of how such cells
minimize the generation of descendants with chromoso-
mal aberrations. One likely possibility is that ES cells
with genetic damage undergo apoptosis. We observed
that a considerable fraction of ES cells did not attach to a
solid support following irradiation, and some cultures
exhibited a sub-G1 fraction (Figure 2). Adriamycin treat-
ment also caused a dose-dependent death response, most
cells detaching from the plate 24 hours after irradiation
(Figure 6a). DNA isolated from such cells displayed the
ladder pattern commonly generated in the later stages of
apoptosis (Figure 6b). We further substantiated that ES
cells undergo apoptosis in response to DNA damage
using a terminal-deoxynucleotidyltransferase-mediated
dUTP nick end-labeling (TUNEL) assay. Figure 6c
shows that many ES cells treated with adriamycin for
more than eight hours were TUNEL positive and exhib-
ited the pattern of nuclear DNA fragmentation that typi-
fies apoptosis [52]. 
As ES cells do not arrest in G1 phase upon challenge with
antimetabolites, such cells may acquire DNA damage due
to replication with an insufficient nucleotide supply
[6,15,29]. Under these conditions, ES cells with normal
p53 may be susceptible to apoptosis because continued
DNA synthesis after nucleotide-pool depletion may lead
to DNA breakage. We therefore determined whether
PALA treatment induced apoptosis in ES cells. TUNEL
analysis showed that 10–15% of the cells treated with
PALA for 16 hours demonstrated the massive DNA
breakage characteristic of apoptosis (Figure 6c). This pro-
portion was less than that seen when ES cells were
treated with adriamycin whereby > 40% of the cells were
TUNEL positive (Figure 6c), so we infer that PALA is
less effective at inducing DNA damage than adriamycin
under the stated conditions. 
We determined whether apoptosis in ES cells required
p53 by measuring the apoptotic response of ES cells in
which the p53 gene was inactivated by homologous
recombination. The p53-positive and p53-negative cell
populations were killed by adriamycin in a similar dose-
dependent fashion (Figure 6a) and equivalent fractions of
p53-positive and p53-deficient cells underwent apoptosis
(Figure 6c). Furthermore, although the exact frequency of
apoptosis was difficult to quantitate in ES cell clumps, it is
clear that kinetics of the apoptotic response were similar
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Figure 5
Cell-cycle profiles of adenovirus-infected ES cells in the presence and
absence of PALA. Cells were infected with a control adenovirus
expressing β-galactosidase (c; 1010 virus particles per 5 × 105 cells) or
with the p53-expressing ACNp53 virus (p53; 5 × 109 particles per
5 × 105 cells) in the presence or absence of 1 mM PALA. Similar
results were obtained in two other independent repetitions of the
infection and treatment on two independently derived strains of ES
cells. 
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in p53-positive and p53-negative cells (Figure 6c). These
results indicated that p53 is not required for the damage-
induced apoptotic response in ES cells.
Restoration of the PALA-induced cell-cycle-arrest response
upon differentiation
The lack of the p53-mediated cell-cycle arrest response
in ES cells strongly contrasts with the PALA-induced
arrest response observed in normal MEFs. Because p53
levels in ES cells are high initially and are subsequently
reduced and because expression becomes limited to spe-
cific cell lineages during development [40], it is possible
that the p53 response is designed to ensure that the cell-
cycle arrest pathway can be activated rapidly upon differ-
entiation of the inner cell mass. To test whether
differentiation restores the arrest response, we analyzed
the cell-cycle profile of ES cells grown in a medium
without the cytokine leukemia inhibitory factor (LIF),
supplemented with retinoic acid and treated with PALA.
As shown in Figure 7, the S-phase fraction in the differ-
entiated ES cells was reduced to about 25% and was
further diminished by PALA treatment. These results
show that the ability to arrest the cell cycle in response to
antimetabolite challenge could be restored when ES
cells differentiate.
Discussion
Chemical and physical challenges that may lead to genetic
instability failed to induce cell-cycle arrest in undifferenti-
ated murine ES cells but were able to induce apoptosis.
The normal cell cycle of ES cells consists predominantly
of alternating phases of DNA synthesis and mitosis, with
very short G1 and G2 intervals, leading to an 8 hour dou-
bling time (data not shown). These data are compatible
with earlier inferences of 5–6hour cell cycles of ES cells in
vivo [53]. Very short cell cycles have been observed during
early embryogenesis, such as in Drosophila [54] and
Xenopus (the first 12 divisions) [55]. In these systems,
replication is accelerated and occurs in the absence of
transcription. Conversely, cells from the murine inner cell
mass do not change the length of the S phase but appear
to abbreviate G1 and, perhaps, G2 ([56]; this work). The
lack of G1 and G2 correlates with the inactivation of the
cell-cycle checkpoint controls that usually operate during
these intervals. In early embryogenesis, guaranteeing
accurate repair may be incompatible with rapid replicative
cycles, and elimination of damaged cells may represent a
safer alternative to cell-cycle arrest. Although this strategy
exposes ES cells to the hazards of DNA replication and
cell division under suboptimal conditions, the efficient
apoptotic mechanism described here provides effective
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Figure 6
p53-independent apoptosis in adriamycin-
treated ES cells. (a) Survival of p53-positive
and p53-negative ES cell populations after a
16 h exposure to increasing doses of
adriamycin. (b) Agarose gel electrophoresis of
low molecular weight DNA from untreated ES
cells (lane 2) or ES cells that were exposed to
adriamycin for 16 h (lane 3). Lane 1, 1 kb
ladder (BRL). (c) TUNEL assay for detection
of DNA breaks in ES cells. Upper panels,
p53+/+ cells; lower panels, p53–/– cells. ES
cells were exposed to 1 µg/ml adriamycin for
the indicated times or with 0.5 mM PALA for
16 h. Fluorescent cells were visualized with an
FITC filter. 
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insurance against the possibility of genetically damaged
cells contributing to the developing organism. 
Two components of the damage-induced cell-cycle check-
point control pathway, p53 and Mdm2, were detected in
ES cells. We could not, however, detect any p21 protein,
basal levels of which are largely determined by transcrip-
tional activation by p53 [57]. The p53 protein was found
mainly in the cytoplasm of ES cells and formed a complex
with Mdm2. Nevertheless, our data suggest that neither
sequestration of p53 in the cytoplasm nor inactivation by
Mdm2 was entirely responsible for the lack of cell-cycle
arrest upon DNA damage, because PALA-treated ES cells
manifested some nuclear p53, and overexpression of
normal nuclear p53 by viral infection did not induce cell-
cycle arrest. The lack of cell-cycle arrest therefore derives
from additional dysfunctions downstream of p53 in the
damage response pathway. 
Our results show that conditions leading to a p53-depen-
dent cell-cycle arrest in MEFs activate a p53-independent
apoptotic mechanism in ES cells. Apoptosis can be
induced by rapid growth in the presence of excess p53
[58], by induction of viral oncogenes [17,59,60], or by
deletion of Rb protein in the presence of normal levels of
p53 [26,61]. Growth factor modulations may also induce
apoptosis in fibroblasts that would normally arrest follow-
ing DNA damage [17,18]. In such fibroblasts, rapid growth
may bypass the arrest pathway by not allowing cells to
linger long enough before the G1 restriction point, leading
to unscheduled DNA replication, DNA damage and apop-
tosis. We note that apoptotic indices and survival curves in
p53-positive and p53-negative ES cells were experimen-
tally indistinguishable after adriamycin treatment, indicat-
ing little if any contribution of p53 function to apoptosis in
the ES cells. Apoptosis that is p53 independent was also
observed in somatic cells [14,62]. One mechanism for p53-
independent apoptosis may be through another protein,
related to p53, that responds to different challenges in dif-
ferent tissues, such as the recently described p73 protein
[63]. It is also formally possible that the p53-independent
apoptotic pathway in ES cells is activated concomitant
with a p53-dependent pathway. Nevertheless, because
p53 overexpression did not induce apoptosis, we infer that
a p53-dependent apoptotic pathway in the absence of
DNA damage is difficult to activate in ES cells. This strin-
gent inactivation may allow ES cells to undergo rapid cell
divisions without the potential inhibitory effects produced
by transactivation of p53 targets. 
Another mechanism for p53-independent apoptosis is sug-
gested by experiments in somatic cells, in which apoptosis
is induced by elevated activity of the transcription factor
E2F-1. This can be achieved by Rb inactivation [64],
overexpression of Myc [17,18] or by transfection with
cDNA encoding the E2F-1 DNA-binding domain [65,66].
Tumor cells deficient in both p53 and Rb undergo apopto-
sis in response to DNA damage and this apoptosis can be
prevented by the expression of Rb [67]. Thus, it is tempt-
ing to speculate that a dysfunction in the Rb-mediated
inhibition of E2F activity may lead to deregulation of E2F
in ES cells and may render the cells exquisitely sensitive
to apoptosis upon DNA damage. Indeed, most of the Rb
protein is present in the proliferative form in ES cells
([56]; data not shown). Furthermore, cyclin D and its asso-
ciated cyclin-dependent kinase CDK4, which modify Rb
in somatic cells, are not functional in ES cells [48]. 
Our data suggest that the lack of arrest in ES cells reflects
a cell cycle driven by fewer cyclins than in somatic cells,
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Figure 7
Cell-cycle profiles of differentiated ES cells
after exposure to PALA. ES cells were
differentiated by removal of LIF and exposure
to retinoic acid in the growth medium. Cells
were then left untreated (control) or exposed
to 100 µM PALA for 24 h, then allowed to take
up BrdU for 30 min, harvested and analyzed
for cell-cycle profiles as detailed in the legend
to Figure 1.
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and some checkpoint controls may be inactivated as a con-
sequence. This interpretation is consistent with other
observations suggesting that some early embryonic cell
cycles differ from the somatic cell cycle [68,69]. Cell divi-
sions during early Xenopus embryogenesis, for example,
seem to be driven by a single cyclin-dependent kinase,
p34cdc2 (also known as maturation promoting factor, MPF)
[69]. Extracts of Xenopus eggs continue to cycle in the
absence of DNA replication or spindle formation [55].
There are other examples, such as fission yeast, in which
the cell cycle is driven by a single functional and essential
cyclin [70], while other non-essential cyclins enable
further layers of control to be implemented. 
The absence of components of the p53-mediated cell-
cycle-arrest-response pathway in ES cells may explain
how embryonic cells can divide very rapidly while
expressing high levels of the normal p53 protein [40].
High levels of apparently normal p53 have also been
observed in embryonic carcinoma cells [71]. The expres-
sion of p53 is down-regulated upon differentiation of
embryonic carcinoma cells and during later stages of
normal embryogenesis, eventually becoming restricted to
only a few specific organ systems [37,40,72,73]. The fluc-
tuations in p53 levels during early embryogenesis imply
some involvement of p53 in embryonic development, yet
studies in p53-deficient mice demonstrate that p53 does
not play an essential role in ontogenesis [23]. On the other
hand, upon exposure to genotoxic stress, mice that express
p53 demonstrate a two- to four-fold lower frequency of
mutant or deformed embryos than mice deficient in p53,
suggesting that p53 may limit the effects of teratogens
[10,12]. Our observations suggest that the p53-mediated
DNA-damage response pathway can become activated
upon differentiation of the inner cell mass. These results
are consistent with data suggesting that, in vivo, differenti-
ated embryonic tissues activate p53 upon DNA damage in
a heterogeneous manner [37]. The activation of p53
response after differentiation may explain why p53-posi-
tive, Mdm2-deficient mouse embryos survive beyond the
inner cell mass stage and then undergo apoptosis in utero
[74]. Presumably, Mdm2 creates a buffer against p53 and
becomes essential for survival only after the p53 pathway
becomes active in differentiated cells. According to this
view, Mdm2 would titrate p53 function to prevent it from
inducing cell-cycle arrest or apoptosis. Our data indicate
that, in early embryogenesis, cell survival does not depend
on the buffer activity of the Mdm2 protein because the
p53 pathway is not yet active. 
Tumors derived from pluripotent cells, such as from tera-
tocarcinomas, are extremely susceptible to apoptosis
upon DNA damage. These tumors express p53 that is
normal in sequence but is not functional [75,76]. In con-
trast to ES cells, teratocarcinoma cells respond to DNA
damage by undergoing p53-dependent apoptosis, but will
also undergo limited apoptosis in the absence of p53.
Similar to ES cells, the lack of damage-induced cell-cycle
arrest reflects the lack of function of a downstream factor
because high levels of p53-dependent transcripts were
not restored upon stabilization of the p53 protein. Taken
with our results, these data suggest that the susceptibility
of these tumors to DNA damage and the lack of a cell-
cycle-arrest pathway that is inducible by DNA damage
may be an inherent characteristic of undifferentiated cells
rather than a peculiar outcome of tumor progression in
these malignancies. 
The lack of checkpoint controls in genotypically normal
ES cells and the acquisition of such checkpoints upon dif-
ferentiation suggest that checkpoint controls may be regu-
lated to various degrees upon differentiation into diverse
cell types. Such variation may explain the apparent redun-
dancy of cell-cycle proteins and pathways and may also
indicate a specialized tissue-specific role for some of the
cell-cycle or damage-sensor proteins. Tissue specialization
of DNA damage and other stress-response arrays may
explain why some cells, such as prostate epithelial cells,
fail to arrest or to induce p53 in response to challenges
that normally activate the p53-dependent cell-cycle-arrest
pathway in genetically identical, adjacent prostate stromal
cells [36]. Heterogeneity in DNA-damage responses may
explain the varied etiologies of malignancies in different
tissues and may also prove relevant to understanding the
molecular basis for the non-random distribution of cancers
in different cell types. 
Conclusions
Wild-type ES cells do not undergo cell-cycle arrest under
conditions, including ribonucleotide depletion and DNA
breakage, that would normally activate the p53-mediated
cell-cycle-arrest pathway in somatic cells (Figure 8). ES
cells express abundant quantities of p53, but the p53-
mediated response is inactive because of cytoplasmic
sequestration of p53, low efficiency of p53 translocation to
the nucleus, and an apparent lack of factors downstream of
p53 in the signal transduction pathway. Nevertheless, ES
cells are still sensitive to conditions that induce DNA
damage, at least in part, because they activate a p53-inde-
pendent apoptotic response. These results suggest that
the relatively low level of developmental abnormalities in
p53-deficient animals is due to the efficient elimination of
damaged cells from the population during early embryo-
genesis. The p53-mediated cell-cycle-arrest response is
restored upon differentiation of ES cells. These data
provide one explanation as to why the embryonic lethality
of Mdm2-deficient mice is delayed until after the inner
cell mass stage. These observations further suggest that
embryonic carcinomas are unable to induce cell-cycle
arrest despite having wild-type p53 because they preserve
the inactive p53-mediated cell-cycle-arrest pathway char-
acteristic of their stem-cell precursors. 
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Materials and methods
Cells culture, treatment and virus infection
Strain 129 ES cells were grown as described [39]. For retinoic acid treat-
ment, cells were plated on non-gelatinized plates containing medium
without LIF, in the presence of 1µM retinoic acid. Cells were allowed to
grow to confluence in this medium, then trypsinized and seeded at a lower
density on new non-gelatinized plates. Cells were allowed to settle on the
plates before treatment with 500µM PALA. The p53–/– ES cells were iso-
lated from embryos derived by a cross between p53–/+ ×p53–/– mice
(strains 129×C57BL6). Blastocysts were explanted and cultured on
feeder cells essentially as described [77]. ES cell lines were sexed by
hybridization to a Y-chromosome-specific probe and genotyped by South-
ern analysis. Cells were supplemented with 1:100 dilution of conditioned
medium from Chinese Hamster Ovary cells producing LIF [39]. MEFs
were obtained from normal and p53-deficient embryos as described [78].
Adenoviruses expressing p53 were gifts from Canji, Inc. PALA was
obtained from the National Cancer Institute and adriamycin from Sigma.
Dose-response curves were obtained by exposure of cells in triplicate to
increasing concentrations of the respective drug for the required period.
Cells were then trypsinized, fixed in 70% ethanol and counted using a
hemocytometer. About 50% of the cells were dying 10h after treatment
with 1µg/ml adriamycin, and this concentration was used for further treat-
ments. Cells were irradiated in liquid medium using a 60Co source (gam-
abeam 150°C), at a rate of 2.9Gy/min at a distance of 40cm. 
Cell-cycle analysis
Cells were incubated in 30 µM BrdU (Fluka) in the growth medium at
37°C, collected by trypsinization, washed with a non-enzymatic PBS-
based cell dissociation medium (Specialty Media Inc.), and fixed in
70% ethanol. ES cells and MEFs were incubated in BrdU for 10 min
and 30 min, respectively, prior to harvesting for cell-cycle analysis,
unless noted otherwise. Each assay involved 5 × 105 cells. The BrdU
content was determined by reaction with a fluorescein isothiocyanate
(FITC)-conjugated anti-BrdU antibody (PharMingen) according to the
manufacturer’s protocol, using propidium iodide–RNase (100 µg/ml)
counterstaining to determine DNA content. Samples were analyzed on
a Becton-Dickinson FACScan using the CellQuest software.
Protein expression
Cells were lysed in NP40 lysis buffer containing 50 mM Tris-HCl,
150 mM NaCl, 1% NP40, pH 8 [79]. Lysates were precleared with
protein G-conjugated agarose beads (Santa Cruz), then reacted with
agarose beads covalently linked to antibody 421 (Santa Cruz), anti-
body sc-812 (Santa Cruz) or to a control antibody (anti-BrdU, PharMin-
gen). Lysates from 107 cells were used for each immunoprecipitation
reaction. Immune complexes were collected by centrifugation, washed
three times in the NP40 lysis buffer and eluted by boiling in gel-loading
buffer [79]. Proteins were separated on 9% discontinuous polyacry-
lamide gels, transferred to BA-83 membrane (Schleicher and Schuel),
blocked in a solution of 5% dry milk and overlaid with antibody accord-
ing to the manufacturer’s instructions. Antibodies Do-1 (Santa Cruz) or
pAb421 (Oncogene Science) were used to detect p53 in the immuno-
complexes and antibody sc-926 (Santa Cruz) was used to detect
Mdm2. The apparent molecular weight of the proteins was calculated
relative to molecular weight standards (BRL) run on the same gel. Pro-
teins were visualized by enhanced chemiluminesence (DuPont NEN)
using an HRP-conjugated goat anti-mouse antibody (Amersham). No
residual p53 protein was detected in the supernatants following
immunoprecipitation (data not shown), suggesting that the lack of
increase was not due to an insufficient amount of antibody.
Immunofluorescence
Cells were grown for at least 16 h on gelatinized 18 mm coverslips
(Sigma), then treated with antimetabolites or DNA damaging agents.
Cells were fixed on coverslips with acetone:methanol (1:1) for 2 min,
permeabilized in PBS containing 0.05% Tween-20 and blocked in
10% horse serum. The coverslips were then overlaid with antibody 421
or Do-1 for 1 h, or with a negative control antibody (anti-BrdU). Excess
antibody was washed four times with the permeabilizing solution. Pro-
teins that reacted with the antibodies were visualized using biotinylated
anti-mouse IgG followed by overlay of avidin–fluorescein. Nuclei were
counterstained with 13 µg/ml Hoechst 33352. Fluorescence was
detected using FITC-specific filters (to detect FITC only) or triple-band-
pass filters to detect FITC and Hoechst staining. All filters were from
Chroma and were used on a Zeiss epifluorescence microscope. Pho-
tographs were taken using Ektachrome 400 ISO color slide film and
scanned to Adobe Photoshop images using a Nikon scanner. For con-
focal analysis, cells were processed in the same way except that the
nuclei were stained for 30 min with propidium iodide in the presence of
40 µg/ml RNAseA. Images were scanned in a BioRad Laser Sharp
confocal microscope and processed in Adobe Photoshop.
TUNEL assay
This was performed using an in situ Cell Death Detection kit
(Boehringer Mannheim) according to the manufacturer’s instructions
except that cells were permeabilized for 2 min in acetone:methanol
(1:1). Treatment with DNAse (1 µg/ml) for 10 min was used as a posi-
tive control for DNA breaks. Fluorescence imaging and photography
were performed as described above.
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